Immunocytochemical Localisation of Prostate-Specific Antigen: Specificity and Application to Clinical Practice

Effects of 3 Months' Neoadjuvant Hormonal Treatment with a GnRH Analogue (Triptorelin) prior to Radical Retropubic Prostatectomy on Prostate-Specific Antigen and Tumour Volume in Prostate Cancer

“…This is of great interest since the tumour tissue content of PSA is much less than in benign tissue. Especially poorly differ entiated tumours seem to express low concentrations of PSA [21] and the hormonal response is often dependent upon the tumour differentiation with a better response in highly and moderately differentiated tumours [12].…”

Clinical Use of Prostate-Specific Antigen in the Staging of Patients with Prostatic Carcinoma

“…Patients with a high-grade tumor (grades III and IV) and PSA level < 10 had tumor confined to the gland. But we believe that high-grade tumors may exhibit extraprostatic tumor even with a low PSA level [9, 25,26], When PSA level of 10 ng/ml was used as the cutoff value to predict extraprostatic tumor, specificity, sensitiv ity and accuracy rates were 47, 97 and 66%, respectively (table 3). When 20 ng/ml was used as the cutoff value, specificity, sensitivity and accuracy rates were 100, 60 and 100%.…”

Serum Prostate-Specific Antigen Discriminates Weakly between Men with Benign Prostatic Hyperplasia and Patients with Organ-Confined Prostate Cancer

“…Serum PSA, for all practical pur poses, is organ-specific, and has been studied extensively as a tumor marker for patients with prostate cancer (CaP) [3,4]. It is well established that following the diagnosis of prostate cancer serum PSA is the preeminent tool for monitoring tumor progression and response to therapy [5][6][7][8], Also, recent screening studies have suggested that serum PSA is useful for detecting early prostate cancer in asymptomatic men of the age range at risk for developing this malignancy [9][10][11][12].…”